.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Evolving Treatment Patterns in Breast Cancer

EP. 1: A Background on Early HER2+ Breast Cancer

January 15th 2019

EP. 2: HER2+ Breast Cancer: The KATHERINE Trial

January 15th 2019

EP. 3: HER2+ Breast Cancer: Use of Weekly Paclitaxel-Trastuzumab

January 15th 2019

EP. 4: Pathologic Complete Response in HER2+ Breast Cancer

January 15th 2019

EP. 5: Current State of CDK4/6 Inhibition in HR+ mBC

January 15th 2019

EP. 6: HR+ Metastatic Breast Cancer: Upfront CDK4/6 Inhibition

January 15th 2019

EP. 7: Making Sense of Adjuvant Therapy in HER2+ Breast Cancer

January 15th 2019

EP. 8: HER2+ Breast Cancer: Neratinibs Role as Adjuvant Therapy

January 15th 2019

EP. 9: Moving CDK4/6 Inhibition to HER2+ Breast Cancer

January 15th 2019

EP. 10: Chemoimmunotherapy in TNBC: The IMpassion130 Trial

January 15th 2019

EP. 11: Combining PARP and Checkpoint Inhibitors in TNBC

January 15th 2019

EP. 12: Antibody-Drug Conjugates in TNBC: Sacituzumab Govitecan

January 15th 2019

EP. 13: Questioning CDK4/6 Inhibitor Cross-Resistance in HR+ mBC

January 15th 2019

EP. 14: Chemoimmunotherapy in TNBC: The KEYNOTE-355 Trial

January 15th 2019